160 related articles for article (PubMed ID: 22123196)
1. The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities.
Teckle P; Peacock S; McTaggart-Cowan H; van der Hoek K; Chia S; Melosky B; Gelmon K
Health Qual Life Outcomes; 2011 Nov; 9():106. PubMed ID: 22123196
[TBL] [Abstract][Full Text] [Related]
2. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.
Marra CA; Woolcott JC; Kopec JA; Shojania K; Offer R; Brazier JE; Esdaile JM; Anis AH
Soc Sci Med; 2005 Apr; 60(7):1571-82. PubMed ID: 15652688
[TBL] [Abstract][Full Text] [Related]
3. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status.
McTaggart-Cowan HM; Marra CA; Yang Y; Brazier JE; Kopec JA; FitzGerald JM; Anis AH; Lynd LD
Qual Life Res; 2008 Apr; 17(3):453-62. PubMed ID: 18274882
[TBL] [Abstract][Full Text] [Related]
4. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
5. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
6. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
7. Discriminative validity of the EQ-5D-5 L and SF-12 in older adults with arthritis.
Tawiah AK; Al Sayah F; Ohinmaa A; Johnson JA
Health Qual Life Outcomes; 2019 Apr; 17(1):68. PubMed ID: 30995930
[TBL] [Abstract][Full Text] [Related]
8. Are condition-specific utilities more valid than generic preference-based ones in asthma? Evidence from a study comparing EQ-5D-3L and SF-6D with AQL-5D.
Kontodimopoulos N; Stamatopoulou E; Brinia A; Talias MA; Ferreira LN
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):667-675. PubMed ID: 30048194
[TBL] [Abstract][Full Text] [Related]
9. The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.
Kontodimopoulos N; Argiriou M; Theakos N; Niakas D
Eur J Health Econ; 2011 Aug; 12(4):383-91. PubMed ID: 20473544
[TBL] [Abstract][Full Text] [Related]
10. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.
Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
Value Health; 2010 Aug; 13(5):649-56. PubMed ID: 20412540
[TBL] [Abstract][Full Text] [Related]
11. How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review.
Papaioannou D; Brazier J; Parry G
Value Health; 2011; 14(6):907-20. PubMed ID: 21914513
[TBL] [Abstract][Full Text] [Related]
12. An investigation into the empirical validity of the EQ-5D and SF-6D based on hypothetical preferences in a general population.
Petrou S; Hockley C
Health Econ; 2005 Nov; 14(11):1169-89. PubMed ID: 15942981
[TBL] [Abstract][Full Text] [Related]
13. "The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction".
Kouwenberg CAE; Kranenburg LW; Visser MS; Busschbach JJ; Mureau MAM
J Plast Reconstr Aesthet Surg; 2019 Jan; 72(1):52-61. PubMed ID: 30270015
[TBL] [Abstract][Full Text] [Related]
14. Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye.
Rajagopalan K; Abetz L; Mertzanis P; Espindle D; Begley C; Chalmers R; Caffery B; Snyder C; Nelson JD; Simpson T; Edrington T
Value Health; 2005; 8(2):168-74. PubMed ID: 15804325
[TBL] [Abstract][Full Text] [Related]
15. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
[TBL] [Abstract][Full Text] [Related]
16. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus.
Aggarwal R; Wilke CT; Pickard AS; Vats V; Mikolaitis R; Fogg L; Block JA; Jolly M
J Rheumatol; 2009 Jun; 36(6):1209-16. PubMed ID: 19369452
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
18. Comparison of EQ-5D and SF-6D utilities in Pompe disease.
Kanters TA; Redekop WK; Kruijshaar ME; van der Ploeg AT; Rutten-van Mölken MP; Hakkaart L
Qual Life Res; 2015 Apr; 24(4):837-44. PubMed ID: 25342117
[TBL] [Abstract][Full Text] [Related]
19. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
Rowen D; Young T; Brazier J; Gaugris S
Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
[TBL] [Abstract][Full Text] [Related]
20. Estimating the relationship between preference-based generic utility instruments and disease-specific quality-of-life measures in severe chronic constipation: challenges in practice.
Parker M; Haycox A; Graves J
Pharmacoeconomics; 2011 Aug; 29(8):719-30. PubMed ID: 21635017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
